About Arch Pharmalabs Limited
Data last updated: 26 July 2025
Arch Pharmalabs Limited is a public limited company based in Mumbai, Maharashtra, India. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 02 April 1993, the company has been in operation for over 33 years.
Registered with ROC Mumbai under CIN U24231MH1993PLC150891.
Capital: an authorised share capital of ₹3,000 Cr and a paid-up capital of ₹156.48 Cr. Formerly known as Sibra Pharmaceuticals Limited and Avant Papers Private Limited. It is led by directors including Vikas Bijay Kedia and Sunil Mansukhlal Pitroda.
Last AGM: 29 December 2023. Financial statements filed for year ended 31 March 2023. Office: Unit No. 301 302 And 303 H Wing 3Rd Floor Tex Centre, Off Saki Vihar Road Chandivali Andheri East Mumbai, Maharashtra, India – 400072.
As per the financials filed for FY 2023, the company reported a revenue of ₹1,344.16 Cr, a growth of 2% compared to the previous year.
The company has a workforce of approximately 412 employees as per the latest available data. Its group structure includes 3 subsidiaries.
The company is associated with 1 brand - Arch Pharmalabs. As per MCA filings, the company has open charges of ₹5,668.24 Cr and satisfied charges of ₹311.84 Cr on record.
The company is undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional, and the company may not be able to independently enter into new commitments. The last known website on record is archpharmalabs.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressUnit No. 301 302 And 303 H Wing 3Rd Floor Tex Centre, Off Saki Vihar Road Chandivali Andheri East Mumbai, Maharashtra, India – 400072
-
IndustryPharma, API Manufacturers, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Arch Pharmalabs Limited
Arch Pharmalabs Limited has undergone 3 name changes throughout its history. The company was previously known as Sibra Pharmaceuticals Limited, Avant Papers Private Limited, and Arch Commerz Limited. The current legal name is Arch Pharmalabs Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Arch Pharmalabs Limited | Current |
| Sibra Pharmaceuticals Limited | Previous |
| Avant Papers Private Limited | Previous |
| Arch Commerz Limited | Previous |
CIN History of Arch Pharmalabs Limited
Arch Pharmalabs Limited has one previous CIN (Corporate Identification Number): U24231MH2005PTC150891. The current CIN is U24231MH1993PLC150891, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231MH1993PLC150891 | Current |
| U24231MH2005PTC150891 | Previous |
Associated Brands with Arch Pharmalabs Limited
Arch Pharmalabs Limited operates one associated brand: Arch Pharmalabs. These brands represent Arch Pharmalabs Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| API manufacturer & supplier, also offering custom synthesis and contract manufacturing services | archpharmalabs.com |
Competitors & Alternatives of Arch Pharmalabs Limited
Brands and companies operating in the same space as Arch Pharmalabs Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Arch Pharmalabs Limited
Arch Pharmalabs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Arch Pharmalabs Limited
Arch Pharmalabs Limited is audited by Neha C Shah & Associates for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Neha C Shah & Associates | blur-value | blur-value | blur-value |
Board of Directors of Arch Pharmalabs Limited
Arch Pharmalabs Limited is currently managed by 7 directors, with 26 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vikas Bijay Kedia | Company Secretary | 18 Nov 2017 | 8 Years 7 Months | As last reported |
| Sunil Mansukhlal Pitroda | Director | 02 May 2017 | 9 Years 2 Months | As last reported |
|
Anshul Gupta
Also directs:
Finkonnect Capital Advisors Llp, Afro Connect Consultancy Services Private Limited, Yajur Veda Impex Private Limited and 1 more
|
Irp/Rp/Liquidator | 30 Apr 2025 | 1 Years 2 Months | As last reported |
|
Ajit Annu Kamath
Also directs:
Vitalife Pharma Limited, Tack Commosales Llp, Arch Agro Industries Private Limited and 5 more
|
Managing Director | 01 Nov 2003 | 22 Years 8 Months | As last reported |
|
Rajendra Padmanabhan Kaimal
Also directs:
Vitalife Pharma Limited, Arch Agro Industries Private Limited, Amra Renal Care Limited and 5 more
|
Whole-Time Director | 01 Nov 2003 | 22 Years 8 Months | As last reported |
|
Ashish Mohan Ujagare
Also directs:
Vitalife Pharma Limited
|
Whole-Time Director | 14 Jun 2018 | 8 Years 0 Months | As last reported |
Financials of Arch Pharmalabs Limited FY 2023 filings available
Arch Pharmalabs Limited reported revenue of ₹1,344.16 Cr (up 2% YoY) for FY 2023. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Arch Pharmalabs Limited
As of FY 2023, Arch Pharmalabs Limited's shareholding pattern shows 58.13% by promoters, 41.18% by public shareholders, 0.69% by others. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Arch Pharmalabs Limited
Arch Pharmalabs Limited has 3 subsidiary companies and 1 associated company. This group structure data is as of FY 2023. The corporate group structure reflects Arch Pharmalabs Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Arch Finechemicals Limited | U24110TG1993PLC015533 |
**.**%
|
| Arch Life Sciences Limited | U24239TG2003PLC042232 |
**.**%
|
| Vitalife Pharma Limited | U24299MH2021PLC356633 |
**.**%
|
Showing major subsidiaries. Total: 3.
Charges & Borrowings of Arch Pharmalabs Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Mar 2022 | Others | ₹32 Cr | Open |
| 20 Jul 2021 | Others | ₹5 Lakh | Open |
| 27 May 2021 | Others | ₹200 Cr | Open |
| 04 Dec 2017 | Others | ₹200 Cr | Open |
| 27 Sep 2013 | Others | ₹582.3 Cr | Open |
Total charge records: 65 View all charges
Employees and EPFO Compliance at Arch Pharmalabs Limited
Arch Pharmalabs Limited has a workforce of 412 employees as of Apr 08, 2024.
Employee Count & EPFO Data of Arch Pharmalabs Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Arch Pharmalabs Limited
GSTIN & GST Filing Data of Arch Pharmalabs Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Arch Pharmalabs Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Arch Pharmalabs Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Arch Pharmalabs Limited
MSME Payment Delays by Arch Pharmalabs Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Arch Pharmalabs Limited
Subsidiaries & Group Companies of Arch Pharmalabs Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Arch Pharmalabs Limited with ownership details.
MCA Filings & Documents of Arch Pharmalabs Limited
MCA Filings & Documents of Arch Pharmalabs Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Arch Pharmalabs Limited
Recent News on Arch Pharmalabs Limited
Frequently Asked Questions about Arch Pharmalabs Limited
Arch Pharmalabs Limited is undergoing "Corporate Insolvency Resolution Process" (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency resolution professional. The company may not be able to independently enter into new commitments during this period. This is a high-risk status - verify the resolution status before any engagement.
Arch Pharmalabs Limited is a company under insolvency, formerly operating as a public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 02 April 1993 and is registered under CIN U24231MH1993PLC150891. Caution is advised - the company may not have the legal capacity to fulfil new agreements.
Arch Pharmalabs Limited reported revenue of ₹1,344.16 Cr for FY 2023 (up 2.00% YoY).
The current directors of Arch Pharmalabs Limited are:
- Vikas Bijay Kedia
- Rajendra Padmanabhan Kaimal
- Sunil Mansukhlal Pitroda
- Anshul Gupta
- Ajit Annu Kamath
- Ashish Mohan Ujagare
- Rajendrakumar Padmanabhan Kaimal
The CIN (Corporate Identification Number) of Arch Pharmalabs Limited is U24231MH1993PLC150891. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Arch Pharmalabs Limited has open charges of ₹5,668.24 Cr and satisfied charges of ₹311.84 Cr as per latest MCA filings.